
When cancer cells in male patients and immune cells in their tumors both lose the Y chromosome, those patients tend to experience poorer outcomes than patients without Y chromosome loss, according to new findings from Cedars-Sinai investigators. Their work, published in the scientific journal Nature[1], could lead to ways to make some cancer treatments more effective.
The Y chromosome is one of two chromosomes that determine biological sex in mammals. Females have two X chromosomes, males have one X and one Y chromosome, and it is common for males to lose the Y chromosome in some of their cells as they age.
Cedars-Sinai research published in 2023 found that loss of the Y chromosome in bladder cancer cells in men helped those cells evade the body’s immune system, allowing the cancer to grow[2].
However, tumors with loss of the Y chromosome also were more susceptible than those with an intact Y chromosome to immune checkpoint therapy.
Given the previous findings, that Y chromosome loss in cancer cells was problematic in most male tumors, study co-senior authors Simon Knott, PhD, assistant professor of Biomedical Sciences at Cedars-Sinai, and Dan Theodorescu, MD, PhD, wanted to investigate the consequences of Y chromosome loss in males with other types of cancer, Knott said.
Using large publicly available datasets, the new study examined loss of the Y chromosome in cancer cells from a range of cancers.
Unexpectedly, the investigators found that many other cell types associated with tumors also had Y chromosome loss, prompting further investigations, Knott said.
In addition to the cancer databases, investigators confirmed their findings by looking at loss of Y in patient tumor samples and in preclinical studies using additional techniques to measure Y chromosome loss, which confirmed their findings.
The findings could also have implications for patients receiving T-cell therapies, where immune cells called T-cells are harvested from a patient, altered in the lab so that they are more effective in fighting cancer, then delivered back to the patient.
Further research is needed to help investigators understand how best to adapt these therapies to account for loss of Y.
Additional Cedars-Sinai authors include Xingyu Chen, currently at Johns Hopkins University; Yiling Shen; Suhyeon Choi; Mukta Basu; Lena Hoelzen; Martina Tufano; Hany A. Abdel-Hafiz; Saravana Kumar Kailasam Mani; Maryam Ranjpour; Jiani Zhu; V. Krishnan Ramanujan; Ekaterina K. Koltsova; Vinicius Calsavara; and Dan Theodorescu, currently at the University of Arizona.
Funding: This work was supported in part by NIH grant CA278732.
Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences.
References
1. https://www.nature.com/articles/s41586-025-09071-2
2. https://www.cedars-sinai.org/newsroom/loss-of-y-chromosome-in-men-enables-cancer-to-grow/
(Newswise/PPP)